Article

Comorbidity and Survival Disparities Among Black and White Patients With Breast Cancer

Department of Community Health Sciences, Brock University, St Catharines, Ontario, Canada.
JAMA The Journal of the American Medical Association (Impact Factor: 30.39). 11/2005; 294(14):1765-72. DOI: 10.1001/jama.294.14.1765
Source: PubMed

ABSTRACT Reasons for the shorter survival of black breast cancer patients compared with their white counterparts are not completely understood.
To evaluate the role of comorbidity in this racial disparity among breast cancer patients.
Historical cohort from the Henry Ford Health System (a large comprehensive health system in Detroit, Mich) followed up for a median of 10 years. Patients (n = 906) included 264 black (29.1%) and 642 white (70.9%) women diagnosed as having breast cancer between 1985 and 1990. Detailed comorbidity data (268 comorbidities) and study data were abstracted from medical records and institutional, Surveillance, Epidemiology, and End Results, and Michigan State registries. Associations were analyzed with logistic and Cox regression.
Breast cancer recurrence/progression and survival to death from all, breast cancer, and competing (non-breast cancer) causes.
Of blacks, 64 (24.9%) died of breast cancer and 95 (37.0%) died of competing causes. Comparable data for whites were 115 (18.3%) and 202 (32.1%). Blacks had worse all-cause survival (hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.11-1.62), breast cancer-specific survival (HR, 1.47; 95% CI, 1.08-2.00), and competing-causes survival (HR, 1.27; 95% CI, 1.00-1.63). A total of 77 adverse comorbidities were associated with reduced survival. Adverse comorbidity count was associated with all-cause (adjusted HR, 1.29; 95% CI, 1.19-1.40) and competing-causes survival but was not associated with recurrence/progression or breast cancer-specific survival. At least 1 adverse comorbidity was observed in 221 (86.0%) blacks and 407 (65.7%) whites (odds ratio, 3.20; 95% CI, 2.17-4.72). Comparisons of unadjusted and comorbidity-adjusted HRs indicated that adverse comorbidity explained 49.1% of all-cause and 76.7% of competing-causes survival disparity. Diabetes and hypertension were particularly important in explaining disparity.
More black breast cancer patients die of competing causes than of breast cancer. Effective control of comorbidity in black breast cancer patients should help improve life expectancy and lead to a reduction in survival disparities.

0 Followers
 · 
140 Views
 · 
1 Download
  • Source
    • "It is of particular interest that some of the pathways identified as important, such as (mammalian target of rapamycin) MTOR/rapamycin and histone deacetylase, are potential therapeutic targets. It will also remain important to continue to investigate other factors that may contribute to inferior outcomes among younger women [78]. "
  • Source
    • "Finally, several investigations report that more AA breast ISRN Oncology cancer patients die from their medical comorbidities than from complications of their breast cancer [18]. A large majority of AA females receive their medical care from community hospitals. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer survival has significantly improved over the past two decades. However, the diagnosis of breast cancer is lower and the mortality rate remains higher, in African American women (AA) compared to Caucasian-American women. The purpose of this investigation is to analyze postoperative events that may affect breast cancer survival. This is a retrospective analysis of prospectively collected data from The Brooklyn Hospital Center cancer registry from 1997 to 2010. Of the 1538 patients in the registry, 1226 are AA and 269 are Caucasian. The study was divided into two time periods, 1997-2004 (period A) and 2005-2010 (period B), in order to assess the effect of treatment outcomes on survival. During period A, 5-year survival probabilities of 75.37%, 74.53%, and 78.70% were seen among all patients, AA women and Caucasian women, respectively. These probabilities increased to 87.62%, 87.15% and 89.99% in period B. Improved survival in AA women may be attributed to the use of adjuvant chemotherapy, radiation, and hormonal therapy. Improved survival in Caucasian patients was attributed to the use of radiation therapy, as well as earlier detection resulting in more favorable tumor grades and pathological stages.
    02/2014; 2014:694591. DOI:10.1155/2014/694591
  • Source
    • "Hypertension is reported regularly in cancer patients, with estimates of HTN approaching or eclipsing 40% in cancer populations [4, 8–13]. The reported HTN prevalence is even higher in elderly and black cancer patients [4, 8, 11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This retrospective cohort study was conducted to estimate incidence rates of new-onset hypertension in adult cancer patients identified from the Varian Medical Oncology outpatient database. Incidence rates of increasing levels of hypertension severity were calculated overall and for periods of chemotherapy exposure and nonexposure. Cox models sought predictors of new-onset hypertension severity among baseline and chemotherapy exposure variables. New-onset hypertension was observed in about one-third of 25,090 patients with various cancer types. The incidence rates (IR) of severe and crisis-level hypertension, respectively, were the highest in patients with gastric (18.5 cases per 100 person-years (PY), 5.6 per 100 PY) and ovarian cancer (20.2 per 100 PY, 4.8 per 100 PY). The highest IR of moderate hypertension was observed in patients with renal cancer (46.7 per 100 PY). Across all cancers, chemotherapy exposure was associated with a 2-3.5-fold increase in risk of any degree of hypertension compared to periods of no chemotherapy; higher hypertension levels showed greater variability in relative risks by type and line of therapy but indicated an overall increase associated with chemotherapy exposure. These results help to elucidate the factors influencing HTN among cancer patients and the incidence of HTN relative to chemotherapy exposure.
    International Journal of Hypertension 12/2013; 2013:379252. DOI:10.1155/2013/379252
Show more

Preview

Download
1 Download
Available from